My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Prometheus Biosciences, Inc. - Common Stock (NQ:RXDX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Prometheus Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday ↗

December 08, 2022

Via Benzinga

Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 07, 2022

U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds.

Via Benzinga

Dow Edges Higher; Prometheus Biosciences Shares Jump ↗

December 07, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 07, 2022

Via Benzinga

Nasdaq Drops 75 Points; Crude Oil Down 2% ↗

December 07, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday.

Via Benzinga

Why Shares of Prometheus Biosciences Slumped This Week ↗

December 02, 2022

The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.

Via The Motley Fool

Expert Ratings for Prometheus Biosciences ↗

August 29, 2022

Within the last quarter, Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings:

Via Benzinga

Analyst Ratings for Prometheus Biosciences ↗

August 29, 2022

Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:

Via Benzinga

Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session ↗

December 07, 2022

Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...

Via Benzinga

Dow Bounces Back From Morning Selloff ↗

December 07, 2022

The Dow Jones Industrial Average is trying to claw back from the market's multi-day selloff. Meanwhile, the S&P 500 Index and Nasdaq Composite Index continue to flag near breakeven.

Via Talk Markets

Analyst Ratings for Prometheus Biosciences ↗

May 13, 2022

Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:

Via Benzinga

PINS Stock Alert: What to Know as Pinterest and Elliott Strike a Deal ↗

December 07, 2022

Pinterest (PINS) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P.

Via InvestorPlace

US Stocks Mixed; Dow Rises 50 points ↗

December 07, 2022

U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 50 points on Wednesday.

Via Benzinga

Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today? ↗

December 07, 2022

Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.

Via InvestorPlace

Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease ↗

December 07, 2022

Prometheus Biosciences made waves Wednesday in irritable bowel disease.

Via Investor's Business Daily

These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday ↗

December 07, 2022

Even as broader markets fell, these companies announced great news.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 07, 2022

Via Benzinga

Prometheus Biosciences Stock Skyrockets After Favorable Data From Ulcerative Colitis, Crohn's Disease Studies ↗

December 07, 2022

Via Benzinga

Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here's What You Need To Know ↗

October 04, 2022

Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00. Shares of Prometheus Biosciences are trading down...

Via Benzinga

Where Prometheus Biosciences Stands With Analysts ↗

October 04, 2022

Over the past 3 months, 7 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Delta Air Lines To Rally Around 84%? Here Are 5 Other Price Target Changes For Tuesday ↗

October 04, 2022

Raymond James raised Delta Air Lines, Inc. (NYSE: DAL) price target from $50 to $52. Raymond James analyst Savanthi Syth maintained a Strong Buy rating on the stock. Delta Air shares rose 0.7% to close...

Via Benzinga

7 Top-Rated Biotech Stocks to Buy for Q4 ↗

September 15, 2022

A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Via InvestorPlace

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗

August 30, 2022

Not all shares are slowing down alongside the industry group.

Via Investor's Business Daily

SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers ↗

August 29, 2022

Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading.

Via Benzinga

Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday ↗

August 29, 2022

Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to...

Via Benzinga

Where Prometheus Biosciences Stands With Analysts ↗

August 12, 2022

Over the past 3 months, 4 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

Prometheus Biosciences Stock Shows Rising Relative Strength ↗

July 14, 2022

Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022 ↗

June 10, 2022

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.